PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $11 at Citi
Tweet
Share
E-mailGet Alerts PHAS Hot Sheet
Price: $0.07 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi analyst Joel Beatty lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $11.00 (from $25.00) while maintaining a Buy rating.
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Bill.com Holdings Inc. (BILL) PT Raised to $59 at TD Cowen
- MidCap Financial Investment Corp (MFIC) PT Lowered to $9.50 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
